IBI363
Phase 1Active 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Malignancies or Lymphomas
Conditions
Solid Malignancies or Lymphomas
Trial Timeline
Aug 22, 2022 → Dec 31, 2026
NCT ID
NCT05290597About IBI363
IBI363 is a phase 1 stage product being developed by Innovent Biologics for Solid Malignancies or Lymphomas. The current trial status is active. This product is registered under clinical trial identifier NCT05290597. Target conditions include Solid Malignancies or Lymphomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07402070 | Phase 2 | Recruiting |
| NCT06281678 | Phase 2 | Recruiting |
| NCT06081920 | Phase 2 | Recruiting |
| NCT05460767 | Phase 1 | UNKNOWN |
| NCT05290597 | Phase 1 | Active |
Competing Products
20 competing products in Solid Malignancies or Lymphomas